SLC5A2 and kidney disorder: The results of the dedicated renal trial canagliflozin and renal end points in diabetes with established nephropathy clinical evaluation (CREDENCE) have recently confirmed the effects of SGLT2 inhibitors on the decline of kidney function [169].